In recent years, we have witnessed a real revolution in the medical field, which brings with it new hope for many patients with obesity and chronic diseases associated with it. Medications such as Samgalotide (Antozek, Vigobobi) and Tirazpitide (Mongo), which began as treatments for type 2 diabetes, quickly became major actresses in treating obesity and accompanying morbidity such as heart disease, kidney failure and even sleep disorders. What started as accidental revelations has evolved into a deliberate strategy of developing multi-label drugs. I will present a fascinating picture of this trend here.
* * *
In recent years, the drugs from the GLP-1 receptor egoistic group such as Semlotide (Argspic, Vigobobi) and Tirazpitide (Mongo) have revolutionized obesity and type 2 diabetes. Sleep, addictions, neurological diseases and more.